Dyne Therapeutics (NASDAQ:DYN) Trading Down 3%

Dyne Therapeutics, Inc. (NASDAQ:DYN)’s stock price traded down 3% on Tuesday . The company traded as low as $33.42 and last traded at $33.60. 84,112 shares changed hands during mid-day trading, a decline of 95% from the average session volume of 1,598,878 shares. The stock had previously closed at $34.63.

Analyst Ratings Changes

A number of analysts have recently weighed in on the stock. StockNews.com cut shares of Dyne Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, September 16th. Stifel Nicolaus boosted their target price on shares of Dyne Therapeutics from $41.00 to $66.00 and gave the stock a “buy” rating in a research report on Friday, August 16th. HC Wainwright reaffirmed a “buy” rating and issued a $55.00 price objective on shares of Dyne Therapeutics in a report on Wednesday, September 4th. Morgan Stanley upped their price objective on shares of Dyne Therapeutics from $48.00 to $52.00 and gave the company an “overweight” rating in a report on Wednesday, August 14th. Finally, Guggenheim upped their price objective on shares of Dyne Therapeutics from $45.00 to $50.00 and gave the company a “buy” rating in a report on Thursday, August 15th. One analyst has rated the stock with a sell rating, nine have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $51.40.

Dyne Therapeutics Trading Down 5.9 %

The firm has a market cap of $2.85 billion, a price-to-earnings ratio of -8.72 and a beta of 1.07. The business’s 50-day simple moving average is $40.89 and its two-hundred day simple moving average is $33.71.

Dyne Therapeutics (NASDAQ:DYN) last posted its quarterly earnings results on Monday, August 12th. The company reported ($0.70) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.72) by $0.02. On average, analysts forecast that Dyne Therapeutics, Inc. will post -2.96 earnings per share for the current fiscal year.

Insider Buying and Selling at Dyne Therapeutics

In other Dyne Therapeutics news, COO Susanna Gatti High sold 8,976 shares of the business’s stock in a transaction dated Wednesday, September 18th. The shares were sold at an average price of $34.41, for a total value of $308,864.16. Following the completion of the transaction, the chief operating officer now directly owns 131,636 shares in the company, valued at $4,529,594.76. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Dyne Therapeutics news, COO Susanna Gatti High sold 8,976 shares of the stock in a transaction dated Wednesday, September 18th. The shares were sold at an average price of $34.41, for a total value of $308,864.16. Following the completion of the sale, the chief operating officer now owns 131,636 shares in the company, valued at approximately $4,529,594.76. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO John Cox acquired 32,000 shares of the firm’s stock in a transaction that occurred on Wednesday, September 4th. The stock was acquired at an average price of $33.04 per share, for a total transaction of $1,057,280.00. Following the completion of the acquisition, the chief executive officer now directly owns 8,000 shares of the company’s stock, valued at approximately $264,320. The disclosure for this purchase can be found here. Insiders sold 12,705 shares of company stock worth $437,701 in the last quarter. 20.77% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the company. Nisa Investment Advisors LLC boosted its position in Dyne Therapeutics by 904.1% in the 2nd quarter. Nisa Investment Advisors LLC now owns 743 shares of the company’s stock valued at $26,000 after buying an additional 669 shares during the last quarter. Amalgamated Bank increased its position in shares of Dyne Therapeutics by 39.9% in the second quarter. Amalgamated Bank now owns 2,792 shares of the company’s stock worth $99,000 after acquiring an additional 796 shares in the last quarter. Ameritas Investment Partners Inc. grew its stake in shares of Dyne Therapeutics by 28.0% in the 1st quarter. Ameritas Investment Partners Inc. now owns 5,896 shares of the company’s stock valued at $167,000 after buying an additional 1,291 shares in the last quarter. Public Employees Retirement Association of Colorado bought a new position in shares of Dyne Therapeutics in the 2nd quarter valued at approximately $203,000. Finally, Farallon Capital Management LLC bought a new stake in Dyne Therapeutics during the 2nd quarter valued at approximately $212,000. Institutional investors and hedge funds own 96.68% of the company’s stock.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.